TCP systems and engineering will be consulting SOA in Roche.

Madrid, 2011-October Roche, the largest biotechnology company in the world with drugs truly differentiated in the areas of Oncology, virology, inflammation, metabolism and central nervous system, signed a new project with TCP systems and engineering consulting SOA with Tibco products.

The project was created as part of the new strategy of Roche for the coming years. Very ambitious project since its inception, aims at the introduction of a services-oriented bus based on TIBCO ActiveMatrix product. To ensure the success of this, TCP systems and engineering has been selected as an expert in TIBCO ActiveMatrix Integrator.

The consultancy will define the standards of the different components of the product in such a way that the center of excellence of ROCHE (located in Madrid) to define a standard prototype of installation and configuration of the TIBCO ActiveMatrix product worldwide.

Another important part of the project lies in the development of a plan for testing, documentation and management of incidents with support provided by the manufacturer TIBCO.

About Roche Pharma

Roche, whose headquarters is located in Basel (Switzerland), is a leading company in the health sector, focusing on research and with the combined power of the farmacéutica-diagnóstica integration. Roche is the largest biotechnology company in the world and has drugs truly differentiated in the areas of Oncology, virology, inflammation, metabolism and central nervous system. Roche also is the world leader in in vitro diagnosis, including the histological diagnosis of cancer, and a pioneer in diabetes control. The strategy of Roche in personalized medicine aims to provide medicines and diagnostic tools which make tangible improvements in the health, quality of life and the life expectancy of patients. In 2009, Roche, with more than 80,000 employees around the world, invested nearly 10 billion Swiss francs in research and development. Sales reached 49.100 million Swiss francs. Genentech (United States) is a member of full ownership of the Roche Group. Roche holds a majority stake in Chugai Pharmaceutical (Japan).

About TCP systems and engineering

Endorsed by 19 years of experience in the development and the integration of technology for the medium and large business, TCP systems, engineering, Spanish company with more than 450 workers, has been consolidated in the ICT sector, characterized by high value-added technological solutions.

Aspects such as the orientation towards the customer, flexibility and adaptability, teamwork and the long-term vision made TCP systems and engineering consultancy ICT in strategic decisions of more than 100 large national and international companiesamong the leading companies in banking, telecommunications, industry and public administration.